Drug-likeness widely used to describe physicochemical properties of ligands that are orally bioavailable and therefore the compounds should be biologically active ). An examination of drug-likeness in the condition of oral bioavailability was first reported by Lipinski, Lombardo, Doming, and Feeney in a pivotal analysis which determined the physicochemical properties common to the 90 Th percentile of almost 2500 drugs and candidate drugs reaching Phase II clinical trials .Lipinski defines 'drug-like' compounds that have good absorption, distribution, metabolism and excretion profiles to pass through the clinical trials. He summarized the physicochemical properties present in a drug-like molecule as rule of five. The rule is essential to keep in mind during drug analysis at the same time pharmacologically effective lead structure in develops and step-wise to increase the activity and also selectivity of the compound as well as to confirm drug-like physicochemical properties are managed as described by Lipinski's rule. Applicant drug that ensured to the RO5 move to have lower attrition rates when clinical trials and hence have an increased chance of reaching market.